2010 Adverse reactions

Adverse reactions - 2010

Headlines start at March 2010

“Pfizer Ordered to Pay $1.5 Million in Prempro Damages.”
Bloomberg. 31 December 2010.

“New Drug Approvals Fall in 2010 as Safety Concerns Slow U.S. FDA Decisions.”
Bloomberg. 30 December 2010

“FDA places experimental pain drugs on hold.”
Reuters. 28 December 2010. 

“Regeneron pain drug put on clinical hold by FDA.”
Reuters. 27 December 2010 Reuters. 27 December 2010

“Obecure obesity drug fails trial. In contrast to a previous trial, Obecure's Histalean did not prevent weight gain by patients taking the antipsychotic drug Zyprexa.”
Globes. 24 December 2010

“Ahead of the Bell: Gilead drug failure no surprise. Analyst says late-stage clinical failure of Gilead's ambrisentan comes as no surprise”
Yahoo. 23 December 2010.

 “Cumberland liver failure drug rejected.”
PM Live. 22 December 2010.

“Recombinant Human Growth Hormone (somatropin): Ongoing Safety Review - Possible Increased Risk of Death.”
FDA Medwatch. 22 December 2010

“Heartburn drugs linked to increased pneumonia risk.”
Reuters. 21 December 2010. 

“Astrazeneca Takes $445 Million Charge on Failure of MedImmune RSV Therapy.”
Bloomberg. 21 December 2010

“Anzemet (dolasetron mesylate): Drug Safety Communication - Reports of Abnormal Heart Rhythms.”
FDA Medwatch. 17 December 2010.

“Shares in UK pharmaceutical AstraZeneca drop 5% after US regulators further
delay approval of its heart drug Brilinta.”
BBC website 17th Dec 2010

“Biogen reports four more Tysabri cases, one death.  79 confirmed PML cases as of Dec. 2, with 16 deaths”
Reuters. 16 December 2010.

“Some Medications Raise Risk of Auto Accidents.”
WSJ. 14 December 2010.

“Four Heart Treatments Questioned In Studies.”
WSJ. 14 December 2010.

“Lexicon's experimental arthritis drug disappoints.”
Reuters. 14 December 2010.

“Vioxx harmful even after patients stopped taking it.”
Reuters. 13 December 2010.

“Lilly Suspends Late-Stage Trial for Melanoma Drug in Which 12 People Died.”
Bloomberg. 13 December 2010

“Novartis pulls Zometa submission after breast cancer failure.”
InPharm. 13 December 2010.

“Major US breast cancer drug trial disappoints.”
The Independent. 11 December 2010.

“Pfizer pulls Thelin off market due to liver injury.”
Reuters. 10 December 2010

“US pharmaceutical company takes drug off market.”
Radio Australia News. 10 December 2010.

“Novartis's Failure With Zometa in Breast Cancer Stalls $1 Billion Booster.”
Bloomberg. 10 December 2010.

“J&J Loses First Trial on Warnings of Levaquin Risk.”
Bloomberg. 8 December 2010.

“This posting includes 37 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.”
FDA Medwatch. 8 December 2010.
MedWatch November 2010 Safety Labeling Changes. 

“Commonly used antidepressants may raise heart disease risk.”
Daily Telegraph. 1 December 2010.

“Merck Stops Isentress Trial after Once a day Dosing Fails.”
E Max Health. 1 December 2010.

“Drug made me a sex-crazed transvestite.”
IOL. 30 November 2010.

"No Value in Any Influenza Vaccine: Cochrane Collaboration Study"
Gaia-Health. 6 December 2010.

“French doctors demand to know why drug [benflourex] stayed on the market for so long.”
BMJ 2010; 341:c6882 doi: 10.1136/bmj.c6882. 3 December 2010
No Value in Any Influenza Vaccine: Cochrane Collaboration Study

“FDA staff note risks of AstraZeneca cancer drug.”
Reuters. 30 November 2010

“Glaxo’s Avodart Raises FDA Concern on Cancer Benefits.”
Bloomberg. 29 November 2010.

“FDA staff question Glaxo drug for prostate cancer.”
Reuters. 29 November 2010.

“The Nevada Supreme Court has upheld a $58 million judgment that was awarded to three Nevada women, who claimed they suffered breast cancer after taking the Prempro hormone replacement therapy made by Wyeth, which is now owned by Pfizer (PFE).”
‘Pfizer Loses in Court ... Again’  Seeking Alpha. 26 November 2010.

“Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear.”
‘Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis’
The Lancet, Early Online Publication, 24 November 2010 doi:10.1016/S0140-6736(10)61272-X Cite or Link Using DOI

“$12.6M awarded in drug case. Bone drug caused woman's jaw to disintegrate, jury says.”
Post and Courier. 23 November 2010.

“Canada announces news restrictions on diabetes drug”
Catholic.org. 22 November 2010.

“Darvon Pulled From Market by F.D.A.”
New York Times. 19 November 2010.

“Johnson & Johnson Hid Antibiotic’s Risk, Lawyer Says.”
Bloomberg. 16 November 2010

“Propoxyphene: Withdrawal - Risk of Cardiac Toxicity. Sold as Darvon, Darvocet, and generics.”
FDA Medwatch. 19 November 2010

“Heart drug Multaq linked with 387 reports of adverse effects.”
Sacramento Bee. 19 November 2010.

“Study of Pfizer, Bristol drug halted by bleeding.”
Reuters. 19 November 2010.

“Heart drug raises questions. Report links Multaq with 387 reports of adverse effects.”
JS Online. 19 November 2010

“Health Canada announces restrictions on diabetes drug due to heart risks.”
Winnipeg Free Press. 18 November 2010

“ResVerlogix cholesterol drug fails mid-stage trial.”
Reuters. 17 November 2010.

“Weight loss drug 'caused death of 500 people'.”
Daily Telegraph. 16 November 2010.

“France: Diabetes drug may be linked to 500 deaths.”
Google. 16 November 2010.

“Major new study shows Natrecor is safe, but not very effective.”
LA Times. 14 November 2010. 

“October 2010 Safety Labeling Changes.  This posting includes 34 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE. The "Summary Page" provides a listing of drug names and safety labeling sections revised.”
FDA Medwatch. 13 November 2010

“Blood-clotting drug given to wounded soldiers can cause heart attacks. Trials of NovoSeven, used to halt blood loss, suggest it is no more effective than placebo and raises risk of clots in arteries.”
The Guardian. 13 November 2010

“Acne linked to suicide risk. Acne drugs may make things worse, say scientists.”
The Guardian. 12 November 2010.

“Study on acne suicide risk fuels debate over drugs.”
Reuters. 12 November 2010.

“Lung cancer drug experiment fails.”
Huliq. 11 November 2010.

“Suicide attempts in people taking isotretinoin for acne. Are increased, but the risk is difficult to separate from the higher risk associated with the condition itself.”
BMJ 11 November 2010

“Study links painkillers to reproductive disorders.”
Reuters. 8 November 2010.

“Drugs linked to brain damage 30 years ago. MPs and campaigners predict class action after failures to mount full-scale research into warnings left millions of patients at risk.”
The Independent on Sunday. 7 November 2010.

“..the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07). Median duration of delirium was longer in the rivastigmine group (5·0 days, IQR 2·7—14·2) than in the placebo group (3·0 days, IQR 1·0—9·3; p=0·06).”
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial The Lancet, Early Online Publication, 5 November 2010

“Haemophilia drug can damage heart - study.”
TVNZ. 4 November 2010.

“Are YOUR pills dangerous?”
Daily Mail. 2 November 2010.

“Why the FDA Keeps Saying 'No' to Diet Pills.”
Seeking Alpha. 1 November 2010

“Novartis Officials Hid Bone Drugs' Risks, Lawyer Tells Jurors.”
Bloomberg. 1 November 2010. 

“Firm with Earth City unit is settling suits over drugs tied to suicides.”
STLToday. 30 October 2010.

“Codeine painkillers may be 'unsafe, addictive and ineffective'.”
Daily Mail. 23 October 2010.

“GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update).”
FDA Medwatch. 22 October 2010.

“Federal prosecutors probing Glaxo diabetes pill.”
Sacramento Bee. 21 October 2010 

“More diabetes drug woe for Lilly as teplizumab fails.”
Pharma Times. 21 October 2010.

“Women Are Dying From Hormone Therapy; Why Is Pharma Still Allowed to Push It?”
Alternet. 21 October 2010. 

“September 2010 Safety Labeling Changes:  37 Medical Product Labels with changes to Warnings, Contraindications, Precautions, Adverse Reactions”
FDA Medwatch. 21 October 2010.

“FDA warns of prostate cancer drug risks.”
Reuters. 20 October 2010

“Hormone therapy raises breast cancer deaths: study.”
Reuters. 20 October 2010.

“Drug companies lied to women about HRT risks for nine years”
Journal of the American Medical Association, 2010; 304: 1684-92 20 October 2010

“Pfizer wins HRT trial as new study knocks safety.”
Fiercepharma. 20 October 2010.

“Eli Lilly diabetes drug fails to meet endpoint.”
Marketwatch. 20 October 2010

“Some drugs raising red flags. Illinois doctors are speaking on behalf of pharmaceutical companies, but some of the drugs they're speaking about have come under investigation.”
Chicago Tribune. 18 October 2010

“Should long-term drugs get greater scrutiny?"
Fiercepharma. 18 October 2010.

“Glaxo ready for barrage of lawsuits”
Fiercepharma. 18 October 2010.

“Experts admit swine flu jab 'may cause' deadly nerve disease.”
Daily Mail. 16 October 2010

“FDA warns of fractures with osteoporosis drugs.”
TMC. 16 October 2010.

“Doubts over popular drug.” [reboxetine]
The Age. 15 October 2010.

“F.D.A. Issues Warning on Bone Drugs.”
New York Times. 13 October 2010

“Boehringer Ingelheim withdraws libido drug for women”
BMJ 341:c5701 doi: 10.1136/bmj.c5701. 12 October 2010

“Pfizer's Antidepressant Reboxetine Doesn't Quell Illness, Analysis Find.”
Bloomberg. 13 October 2010.

“Pfizer depression drug ineffective, may be harmful: study.”
Reuters. 13 October 2010. 

“Hormone replacement increases kidney stone risk.”
Reuters. 12 October 2010.

“Novartis's Afinitor Fails to Slow Rare Form of Pancreatic Cancer in Trial.”
Bloomberg. 11 October 2010.

 “Jazz Fails to Win U.S. Approval of Fibromyalgia Drug.”
Bloomberg. 11 October 2010.

“Abbott Pulls Obesity Drug Off The Market.”
RedOrbit. 9 October 2010.

“Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events.”
FDA Medwatch. 8 October 2010. 

“Weight-loss drug withdrawal latest blow to obesity fight.”
Washington Post. 8 October 2010

“Targacept says ADHD drug fails in study.”
BusinessWeek. 7 October 2010.

“Once-Promising Heart Failure Drug Fails in Trial. It's 'the end of the story' for rolofylline against this tough-to-treat condition, researcher says.”
Business Week. 6 October 2010.

“Rosiglitazone and the need for a new drug safety agency.”
BMJ 2010; 341:c5506 doi: 10.1136/bmj.c5506 (Published 6 October 2010)

“Safety worries halt trials of promising biological analgesic.”
BMJ 2010; 341:c5482 doi: 10.1136/bmj.c5482 (Published 5 October 2010).  N Engl J Med2010; doi:10.1056/nejmoa0901510 

“Glaxo's herpes vaccine fails in trial, NIH says.”
Reuters. 30 September 2010.

“Insiders criticise FDA’s decision not to withdraw rosiglitazone”
BMJ 2010; 341:c5333 doi: 10.1136/bmj.c5333 (Published 29 September 2010)  Cite this as: BMJ 2010; 341:c5333

“Incidence of breast cancer falls with less HRT use, Canadian study confirms.”
BMJ  341:c5307 doi: 10.1136/bmj.c5307 (Published 27 September 2010)

“Diabetes drug linked to heart failure.”
3News. 27 September 2010. 

“AstraZeneca drug fails in prostate cancer trial.”
Reuters. 27 September 2010.

“Pfizer ends prostate cancer study of Sutent.”
Business Week. 27 September 2010. 

“Novartis Hid Health Risks of Bone Drugs, Lawyer Tells Jury in New Jersey.”
Bloomberg. 23 September 2010.

“UK study links antipsychotic drugs to clot risk.”
Reuters. 22 September 2010

“FDA sees bowel risk in early Glaxo vaccine data.”
Reuters. 22 September 2010.

“Sanofi Says Experimental Drug Failed in Late Tests.”
Bloomberg. 22 September 2010.

“Actos (pioglitazone): Ongoing Safety Review – Potential Increased Risk of Bladder Cancer.”
FDA Medwatch. 17 September 2010.

“Transition, Lilly kill diabetes program after trial failure.”
Fiercepharma. 17 September 2010. 

“August 2010 Drug Safety Labeling Changes. This posting includes 24 products with safety labeling changes to the following sections: CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.”
FDA Medwatch. 16 September 2010.

“Neurocrine slips on failure of depression drug.”
Google.com. 15 September 2010.

“FDA not impressed with new weight-loss drug.”
Sun-Sentinel. 14 September 2010.

“Bone-Loss Drugs Linked to Higher Risk of Uncommon Thigh Break, Report Says.”
Bloomberg. 14 September 2010. 

“Leukemia Drug Trial Fails.”
New York Times. 13 September 2010.

“More Cancer Treatment Failure.”
AZ Articles. 13 September 2010. 

“Risks of old, new diet drugs face U.S. scrutiny.”
Reuters. 10 September 2010.

“FDA Warns Of Deadly MRI Drug Side Effects. Drugs Said To Cause Rare Skin, Joint Hardening Syndrome.”
WMTW. 10 September 2010.

“U.K. watchdogs vote for Avandia withdrawal.”
Fiercepharma. 7 September 2010.

“Diabetes drug with heart attack link 'should never have been issued'. 'British Medical Journal' says Avandia should be withdrawn from the UK market.”
The Independent. 6 September 2010.

“UK wants GSK's Avandia pulled as EU reviews safety.”
Reuters. 5 September 2010.

“Low IgG Poses Infection Risk With Rituximab.”
Medpage. 3 September 2010. 

“Bone Medicines May Increase Risk of Esophageal Tumors, Researchers Find.”
Bloomberg. 3 September 2010.

“Osteoporosis drug 'doubles cancer risk'.”
Daily Telegraph. 2 September 2010.

“Study Sees Heart Risk in Meridia Diet Pill.”
New York Times. 1 September 2010.

“Tygacil (tigecycline): Label Change - Increased Mortality Risk.”
FDA Medwatch. 1 September 2010

“FDA urged to pull Abbott diet drug from market. Sibutramine, sold under the brand name Meridia, carries heart attack, stroke risks for users with a history of cardiovascular disease.”
Chicago Tribune. 1 September 2010. 

“Drug prescribed for PTSD raises concerns.”
Boston Globe, www.Boston.com. 30 August 2010.

“Forest-Gedeon Richter drug misses overall goal.”
Marketwatch. 30 August 2010. 

“Pfizer settles menopause drug case before retrial.”
Boston.com. 28 August 2010. 

“In Some Patients, Hypertension Meds Raise Blood Pressure. Finding true for "significant" percentage of people, researchers say.”
Business Week. 25 August 2010.

“Diabetes Drug Actos Has Same Heart Risks as Glaxo's Avandia, Study Finds.”
Bloomberg. 25 August 2010.

“Heart risk from diabetes drug Actos as great as from Avandia, study finds.”
LA Times. 24 August 2010.

“FDA studies Novartis drug for cardiovascular risk.”
Bloomberg. 23 August 2010.

“Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk.”
FDA Medwatch. 20 August 2010.

“FDA to review heart risks of Parkinson's drug.”
Reuters. 20 August 2010.

“Painkiller use linked to stroke risk.”
Reuters. 19 August 2010.

“More Cancer Treatment Failure"
Health News. 19 August 2010.

“Post-marketing surveillance of the smoking cessation drug varenicline (Champix) reveals disturbing acts of aggression and violence towards others”
BMJ. 18 August 2010. 341:c4309

“A Cochrane review has found that selective serotonin reuptake inhibitors do not benefit children with autism and in some cases cause harm”
BMJ. 18 August 2010, doi:10.1136/bmj.c4529

“Lilly Stops Alzheimer’s Drug Trials.”
New York Times. 17 August 2010.

“The pharmaceutical industry is a "market for lemons," a market in which the seller knows much
more than the buyer about the product and can profit from selling products less effective and less safe than consumers are led to believe, according to an analysis that will be presented at the 105th Annual Meeting of the American Sociological Association.”
Science Daily. 17 August 2010.

“Five out of six new prescription drugs don't work, doctor claims.”
Daily Telegraph. 17 August 2010.

“FDA considers revoking approval of Avastin for advanced breast cancer.”
Washington Post. 16 August 2010

“UPDATE 3-U.S. proposes withdrawal of Shire hypotension drug.”
Reuters. 16 August 2010

“Midodrine hydrochloride: FDA Proposes Withdrawal of Low Blood Pressure Drug.”
FDA Medwatch. 16 August 2010.

“AstraZeneca to pay $198m to patients over diabetes claims”
BMJ. 13 August 2010, doi:10.1136/bmj.c4422

“Glaxo's anti-seizure drug may cause meningitis: FDA.”
Reuters. 12 August 2010.

“Amgen drug flunks head-and-neck cancer trial.”
Fiercepharma. 11 August 2010. 

“Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis.”
FDA Medwatch. 10 August 2010.

“AstraZeneca to Pay $198 Million for Seroquel Lawsuits.”
Bloomberg. 9 August 2010

“Wyeth hormone drug case opens in Philadelphia.”
Philly.com. 28 July 2010.

“Only some epilepsy drugs may raise suicide risk.”
Reuters. 26 July 2010.

‘Trials of 'unsafe' drug for diabetes stopped.’
Times of India. 23 July 2010

‘Pfizer forced to halt pain drug trials.’
Inpharm. 20 July 2010

‘Glaxo says settles some Paxil birth-defect cases.’
Reuters. 20 July 2010

‘Promising Breast Cancer Drug Fails FDA Test. New Study Shows Little Result Compared To Chemotherapy Alone.’
FoxReno. 19 July 2010

MedWatch June 2010 Drug Safety Labeling Changes.
‘This posting includes 28 products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.’
FDA Medwatch. 16 July 2010.

"GlaxoSmithKline will post a record £1.57billion legal charge during the ­second quarter to settle a host of claims relating to blockbuster diabetes pill Avandia and depression treatment Paxil."
Daily Express. 16 July 2010.

‘FDA panel rejects diet drug.’
Post-Gazette. 16 July 2010.

‘Glaxo pays $460 million to resolve Avandia suits. It was facing more than 13,000 claims alleging that it hid the diabetes drug's heart-attack risk.’
Philadelphia Inquirer. 14 July 2010.

‘Arava (leflunomide): Boxed Warning - Risk of Severe Liver Injury.’
FDA. 13 July 2010.

‘Second big setback for XenoPort: Migraine drug fails test.’
Mercury News. 7 July 2010.

‘Warning on Liver Injury with Propylthiouracil.’
FDA. July 2010.

‘Glaxo, Xenoport migraine drug fails, shares fall.’
Reuters. 7 July 2010.

‘Testosterone Gel Trial Ends After Heart Issue’
New York Times. 5 July 2010.

'Rosiglitazone is linked to heart failure, stroke, and death.'
BMJ.  1 July 2010, JAMA 2010; doi:10.1001/jama.2010.920. Arch Intern Med 2010;

'US FDA probes possible risks of Lilly drug, others.  Lilly's Effient, Sanofi's Multaq under review.' 
Reuters. 30 June 2010

'Study raises questions over wider use of statins'
Reuters. 28 June 2010 

'Lilly’s Effient Tied to More Cancer Risk Than Plavix.'
Bloomberg Business Week. 28 June 2010

‘Merck has lost its first Fosamax jury trial.  A New York jury awarded $8 million in damages to plaintiff Shirley Boles, who claimed her osteonecrosis of the jaw was caused by the bone-building drug.’
Fiercepharma. 28 June 2010

'EU regulators probe risks of blood pressure drugs.'
Reuters. 25 June 2010


'Pfizer shares fall over problems with pain drug.'
Bloomberg Business Week. 24 June 2010

‘Pfizer Suspends Trial of Tanezumab for Osteoarthritis Pain at U.S. Request’
Bloomberg. 23 June 2010

‘Glaxo Settles Nearly 200 Paxil Birth Defect Lawsuits.’
Pharmalot. 23 June 2010.

‘Pfizer pulls leukemia drug from U.S. market.

'Drugmaker Pfizer Inc is pulling a decade-old leukemia medicine off the U.S. market after a study
found a higher death rate and no benefit for patients.’
Reuters. 21 June 2010.

'Mylotarg (gemtuzumab ozogamicin): Market Withdrawal.'
FDA Medwatch. 21 June 2010.

‘Curis Tumbles on Failure of Cancer Drug Trial: Biotech's Latest Mishaps.’
Bullfax. 20 June 2010.

“New study revives cancer fears for Sanofi's Lantus.  Study suggests possible cancer link with high-dose Lantus.”
  Reuters. 18 June 2010.

“Boehringer Sex Pill May Not Aid Women, FDA Staff Say”
Bloomberg. 16 June 2010

“Nexavar fails in lung cancer trial. Inpharm.”
15 June 2010.

“Six malformations associated with valproic acid in pregnancy”
N Engl J Med 2010;362:2185-93  BMJ 15th June 2010

“This posting includes 23 products with safety labeling changes”
FDA Medwatch. 15 June 2010

“Blood Pressure Drugs Linked to Cancer. Angiotensin-Receptor Blockers Raise Risk of Developing Cancer, Research Shows”
WebMD. 14 June 2010

“Therapies for Cancer Bring Hope and Failure.”
New York Times. 14 June 2010.

“Bayer, Onyx: Late-stage lung cancer trial fails.”
Market Watch. 14 June 2010

“Bayer Drug Trial Fails.”
Blogging Stocks. 14 June 2010.

“Common blood pressure drugs may raise cancer risk.”
Reuters. 13 June 2010 

“University Hospitals cardiologists warn of cancer risk in drugs for hypertension, heart failure.”
Cleveland. 13 June 2010

“FDA official attacks safety of Glaxo's Avandia-WSJ.”
Reuters. 11 June 2010.

“FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking the blood pressure medication, Benicar (olmesartan), an angiotensin II receptor blocker, had a higher rate of death from a cardiovascular cause compared to patients taking a placebo.”
FDA Medwatch. 11 June 2010

“Viagra may double hearing loss risk - More study needed.”
Arab Times. 10 June 2010

“Many serious adverse reactions to this year’s seasonal influenza vaccine have occurred across Australia, and its use remains suspended in children aged 5 years and under.”
BMJ 9 June 2010. 2010;340:c2994

“Antiseizure Drug Increases Birth Defect Risk”.
Medpage Today. 9 June 2010. 

“Discovery Labs lung drug disappoints in mid-stage trial.  Drug did not significantly cut artificial breathing time.”
Best Growth Stock. 9 June 2010

“Australian government says healthy under 5s should not be given seasonal flu jab”
BMJ 7 June 2010, doi:10.1136/bmj.c2991

“Two drugs—labetalol and methyldopa—commonly taken for high blood pressure during pregnancy may negatively affect children’s functional development”
BMJ 4 June 2010;340:c2888

“FDA orders new asthma drug warnings to take effect.”
Reuters. 2 June 2010

“Antidepressants known as SSRIs increase risk of cataracts, study says.”
Los Angeles Times. 1 June 2010

“Shares of Marshall Edwards Inc. fell Tuesday after the company said its potential ovarian cancer treatment failed in a late-stage study.”
Bloomberg Business Week. 1 June 2010 

“Glaxo settles more Avandia lawsuits in U.S.”
Reuters. 1 June 2010

“Antidepressants increase miscarriage risk by 68%.”
Daily Mirror. 1 June 2010

“AstraZeneca's Recentin flunks colon cancer tests. Astra won't submit drug for first-line colorectal cancer.”
Reuters. 28 May 2010

“Study links skin reactions to AstraZeneca drug. New product to treat respiratory ailments faces scrutiny from FDA.” 
Delaware Online. 28 May 2010.

“2 drugs’ suicide warnings toughened.”
Boston.com. 26 May 2010

“U.S. warns of liver risk with Glaxo, Roche diet drugs”
Reuters. 26 May 2010.

“Government promises new money for cancer drugs after NICE rejects liver cancer treatment”
BMJ 26th May 2010;340:c2832

“GTx plunges on study failure. GTx drops after company says toremifene did not meet goals in preventing prostate cancer.”
Yahoo News. 26 May 2010

“FDA notified healthcare professionals and patients that it has approved a revised label for Xenical to include new safety information about cases of severe liver injury that have been eported rarely with the use of this medication.”
FDA Medwatch. 26 May 2010

“J&J strengthens warning about suicide on painkillers.”
APP.com. 25 May 2010.

“Cholesterol drug side effects need watching: study.”
Reuters. 20 May 2010

From the website of the US Food & Drug Administration 14 May 2010.
March 2010 - 44 medical products with safety labelling changes due to adverse reactions.

Interactive Investor. 12 May 2010.
"Study of Glaxo platelet drug halted due to clots."

Reuters. 6 May 2010.
"Newron shares plummet 55 pct after drug setback."

Reuters. 5 May 2010.
"U.S. rejects nighttime Tylenol, Excedrin study."

New York Times. 4 May 2010.
"F.D.A. Rejects InterMune’s Drug for Fatal Lung Disease."

Reuters. 4 May 2010.
"Antidepressant tied to risk of newborn heart defect."

Fiercepharma. 4 May 2010.
"FDA probes prostate meds for diabetes, heart risks."

ADVFN. 4 May 2010.
"Trial Of Glaxo 'Red Wine' Drug Suspended; Safety Events Cited."

New York Times. 4 May 2010.
"F.D.A. Rejects InterMune’s Drug for Fatal Lung Disease."

Daily Telegraph. 4 May 2010.
"The Pill linked to low desire for sex, claims study."

Syndey Morning Herald April 23, 2010
“Don’t give children flu jab: chief medical officer”

Reuters. 22 April 2010.
"Pfizer liver cancer trial halted on safety concern."

BMJ.  22 April 2010, doi:10.1136/bmj.c2087
"Anticonvulsant drugs linked to suicidal behaviour."

PJ Online. 22 April 2010.
"Disappointing results for latrepirdine."

InPharm. 21 April 2010.
"GSK lupus drug disappoints in second phase III."

Voxy.nz. 20 April 2010.
"UK Biotech Lays Off Staff After NZ Drug Failure."

Reuters. 18 April 2010.
"FDA mulls killing Avandia safety study: report."

FDA Medwatch. 15 April 2010.
MedWatch March 2010 Drug Safety Labeling Changes.
“This posting includes 40 drug products with safety labelling changes”

FDA Medwatch. 6 April 2010.

“FDA has added a Boxed Warning to the label for propylthiouracil, to include information about reports of severe liver injury and acute liver failure, some of which have been fatal, in adult and pediatric patients using this medication.”

The Scientist. 22 March 2010.
"Alzheimer's drugs hurt brain?"